Radiation dose-response of human tumors
- PMID: 7607946
- DOI: 10.1016/0360-3016(94)00475-z
Radiation dose-response of human tumors
Abstract
Purpose: The dose of radiation that locally controls human tumors treated electively or for gross disease is rarely well defined. These doses can be useful in understanding the dose requirements of novel therapies featuring inhomogeneous dosimetry and in an adjuvant setting. The goal of this study was to compute the dose of radiation that locally controls 50% (TCD50) of tumors in human subjects.
Methods and materials: Logit regression was used with data collected from single institutions or from combinations of local control data accumulated from several institutions treating the same disease.
Results: 90 dose response curves were calculated; 62 of macroscopic tumor therapy, 28 of elective therapy with surgery for primary control. The mean and median TCD50 for gross disease were 50.0 and 51.9 Gy, respectively. The mean and median TCD50 for microscopic disease control were 39.3 and 37.9 Gy, respectively. At the TCD50, an additional dose of 1 Gy controlled an additional 2.5% (median) additional patients with macroscopic disease and 4.2% (median) additional patients with microscopic disease. For both macro- and microscopic disease, an increase of 1% of dose at the TCD50 increased control rates approximately 1% (median) or 2-3% (mean). A predominance of dose response curves had shallow slopes accounting for the discrepancy between mean and median values.
Conclusion: Doses to control microscopic disease are approximately 12 Gy less than that required to control macroscopic disease, and are about 79% of the dose required to control macroscopic disease. The percentage increase in cures expected for a 1% increase in dose is similar for macroscopic microscopic disease, with a median value of approximately 1%/% and a mean of approximately 2.7%/%.
Similar articles
-
In vivo radiation sensitivity of glioblastoma multiforme.Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):99-104. doi: 10.1016/0360-3016(94)00494-6. Int J Radiat Oncol Biol Phys. 1995. PMID: 7721644
-
Dose-response relationship for radiation therapy of subclinical disease.Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):353-9. doi: 10.1016/0360-3016(94)00354-N. Int J Radiat Oncol Biol Phys. 1995. PMID: 7836089
-
Induction thermochemotherapy increases therapeutic gain factor for the fractionated radiotherapy given to a mouse fibrosarcoma.Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):411-7. doi: 10.1016/s0360-3016(97)00037-0. Int J Radiat Oncol Biol Phys. 1997. PMID: 9226330
-
Radiotherapy after prostatectomy: is the evidence for dose escalation out there?Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):346-50. doi: 10.1016/j.ijrobp.2007.10.008. Epub 2008 Jan 30. Int J Radiat Oncol Biol Phys. 2008. PMID: 18234451 Review.
-
Radiation therapy in management of carcinoma of the vulva with emphasis on conservation therapy.Cancer. 1993 Jun 1;71(11):3707-16. doi: 10.1002/1097-0142(19930601)71:11<3707::aid-cncr2820711139>3.0.co;2-u. Cancer. 1993. PMID: 8490921 Review.
Cited by
-
Dosimetric and radiobiological comparison of IMRT, VMAT, and helical tomotherapy planning techniques in hippocampal sparing whole brain radiotherapy with simultaneous integrated boost for multiple brain metastases.Radiat Environ Biophys. 2024 Mar;63(1):47-57. doi: 10.1007/s00411-023-01052-1. Epub 2024 Jan 9. Radiat Environ Biophys. 2024. PMID: 38194100
-
Evaluating the Propagation of Uncertainties in Biologically Based Treatment Planning Parameters.Front Oncol. 2020 Jul 21;10:1058. doi: 10.3389/fonc.2020.01058. eCollection 2020. Front Oncol. 2020. PMID: 32793468 Free PMC article.
-
Using four-dimensional computed tomography images to optimize the internal target volume when using volume-modulated arc therapy to treat moving targets.J Appl Clin Med Phys. 2012 Nov 8;13(6):3850. doi: 10.1120/jacmp.v13i6.3850. J Appl Clin Med Phys. 2012. PMID: 23149778 Free PMC article.
-
On the radiobiological impact of metal artifacts in head-and-neck IMRT in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP).Med Biol Eng Comput. 2007 Nov;45(11):1045-51. doi: 10.1007/s11517-007-0196-8. Epub 2007 Jun 16. Med Biol Eng Comput. 2007. PMID: 17574487
-
Practical approaches to four-dimensional heavy-charged-particle lung therapy.Radiol Phys Technol. 2010 Jan;3(1):23-33. doi: 10.1007/s12194-009-0072-3. Epub 2009 Oct 14. Radiol Phys Technol. 2010. PMID: 20821098 Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources